This study investigates Mesothelin-CAR-T cell immunotherapy for cancers. Mesothelin is a protein that some cancer cells express, and this study looks into using special cells called CAR-T cells to target it.
The study focuses on evaluating the safety, tolerance, and early effectiveness of these CAR-T cells in treating cancers. It is important to understand how well these cells work and how safe they are for patients.
- Who can participate: Adults with advanced cancers that express Mesothelin protein can participate. Participants must have available autologous transduced T cells with greater than or equal to 20% expression of Mesothelin-CAR, a life expectancy greater than 12 weeks, and good organ function.
- Study details: Participants will receive CAR-T cell therapy, where their own T cells are modified to target Mesothelin on cancer cells. Some may also receive antibodies to enhance the treatment. An inactive substance that looks like the investigational medicine/vaccine but does not contain any medicine, called a placebo, will not be used in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand